Opentrons, Pandemic Response Lab

Opentrons, Pandemic Response Lab

Biotechnology, 131 Innovation Dr, Long Island City, New York, 92617, United States, 501-1000 Employees

pandemicresponselab.com

  • LinkedIn

phone no Phone Number: 34********

Who is OPENTRONS, PANDEMIC RESPONSE LAB

As we enter the third year of the COVID-19 pandemic, we recognize that although the pandemic isnt over, it has transitioned into a new phase. In light of a rapidly changing external envir...

Read More

map
  • 131 Innovation Dr, Long Island City, New York, 92617, United States Headquarters: 131 Innovation Dr, Long Island City, New York, 92617, United States
  • 2020 Date Founded: 2020
  • 501-1000 Employees: 501-1000
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from OPENTRONS, PANDEMIC RESPONSE LAB

Opentrons, Pandemic Response Lab Org Chart and Mapping

Employees

Dan Quinlan

Facilities Coordinator

Michael Davidson

Laboratory Information Systems Administrator

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Opentrons, Pandemic Response Lab

Answer: Opentrons, Pandemic Response Lab's headquarters are located at 131 Innovation Dr, Long Island City, New York, 92617, United States

Answer: Opentrons, Pandemic Response Lab's phone number is 34********

Answer: Opentrons, Pandemic Response Lab's official website is https://pandemicresponselab.com

Answer: Opentrons, Pandemic Response Lab's revenue is $25 Million to $50 Million

Answer: Opentrons, Pandemic Response Lab has 501-1000 employees

Answer: Opentrons, Pandemic Response Lab is in Biotechnology

Answer: Opentrons, Pandemic Response Lab contact info: Phone number: 34******** Website: https://pandemicresponselab.com

Answer: As we enter the third year of the COVID-19 pandemic, we recognize that although the pandemic isnt over, it has transitioned into a new phase. In light of a rapidly changing external environment, we have made the difficult decision to wind down operations for PRL effective 12/31/22 and make a strategic pivot to center our lab services on non-clinical lab customers. This shift points our company to areas where we can make the most significant impact in the most differentiated way. We will no longer be accepting samples after 12/27 and will reassign our sequencing core and biosurveillance activities to our sister company Neochromosomes biofoundry operations. We are grateful to everyone who contributed to making PRL an invaluable public health resource and a successful business during the COVID-19 pandemic. Thank you for the opportunity to serve. The PRL Team

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access